Table 1.
Circulating microRNAs in acute myocardial infarction studies
| microRNA | Fold change, increase or decrease | ROC (AUC) | Correlation | Time of blood sampling | No. samples | Species | Reference |
|---|---|---|---|---|---|---|---|
| miR-1 | 300↑ | 0.98 | TnT | < 12 h, > 12 h, day 2, day 3, > 1 month | 25 STEMI, | Human | [39••] |
| miR-133a | 70↑ | 0.86 | 11 healthy | Pig | |||
| miR-208b | 3000↑ | 1.00 | 6 closed | ||||
| miR-499 | 250↑ | 0.99 | chest MI | ||||
| miR-208a | nd | ||||||
| miR-1 | 60↑ | 0, 30, 60, 90, 120 and 150 min | |||||
| miR-133a | 60↑ | ||||||
| miR-208b | 80↑ | ||||||
| miR-499 | 60↑ | ||||||
| miR-1 | All four significantly ↑ | 0.85 | 4.8 ± 3.82 | 33 AMI, | Human | [40••] | |
| miR-133a | 0.87 | 17 non-CHD, 16 CHD | |||||
| miR-208a | 0.97 | 6 non-op, | |||||
| miR-499 | 0.82 | 6 sham-op, | |||||
| miR-1 | 500↑ | 1, 3, 6, 12, and 24 h after the ligation | 6 coronary artery ligation | Rat | |||
| miR-133a | 750↑ | ||||||
| miR-208a | 850↑ | ||||||
| miR-499 | 40↑ | ||||||
| miR-1 | ns | < 12 h | 32 AMI, | Human | [44••] | ||
| miR-133a | 4↑ | 36 controls | |||||
| miR-208b | 1600↑ | 0.94 | TnT | ||||
| miR-499 | 100↑ | 0.92 | TnT | ||||
| miR-1 | 16↑ | 517 ± 309 min | 33 STEMI, 17 healthy donors | Human | [38••] | ||
| miR-133a | 140↑ | ||||||
| miR-133b | 60↑ | ||||||
| miR-499-5p | 100↑ | ||||||
| miR-208a | nd | ||||||
| miR-1 | 6↑ | 15 min to 5 d | 4–5 coronary artery ligation and sham operated | Mouse | |||
| miR-133a | 13↑ | ||||||
| miR-133b | 5↑ | ||||||
| miR-499-5p | 60↑ | ||||||
| miR-208a | ↑ | ||||||
| miR-499 | 62↑ | CK-MB | 48 h | 9 AMI, 5 UAP, 9 CHF_III, CHF_II, normal controls | Human | [49] | |
| miR-1 | 61%↑ | 0.77 | QRS widening | 93 AMI, 66 controls | Human | [41••] | |
| mir-133 | ns | ||||||
| miR-1 | 20–100↑ | CK-MB | 8.5 ± 3.82 | 31 AMI, 20 controls | Human | [42••] | |
| 200↑ | Infarct size in vivo | 0, 1 h, 3 h, 6 h, 12 h, 24 h, 3 d, 7 d, 14 d, 21 d, and 28 d | 8–12 LAD ligation, 8–12, sham operated | Rat | |||
| Cell damage in vitro | |||||||
| miR-133 | 4.4↑ | 0.89 | 5.24 ± 1.38 h, 20 h, 7 d | 51 AMI, | Human | [69] | |
| miR-328 | 10.9–16.1↑ | 0.81 | 28 controls | ||||
| miR-145 | 2↑ | Hs-TnT | 3.0 ± 2.3 h, 3 d, 4 d | 20 STEMI, | Human | [52•] | |
| miR-30c | 1.3 ↑ | Hs-TnT | 20 controls, | ||||
| miR-1291 | 4.5 ↓ | 0.91 | 20 internal control | ||||
| miR-663b | 2 ↓ | 0.94 | |||||
| miR-1 | ↑ | eGFR, hs-TnT | 117 UAP, | Human | [43••] | ||
| miR-133a | ↑ | eGFR, age,hs-TnT | 131 NSTEMI, | ||||
| miR-133b | ns | hs-TnT | 196 STEMI | ||||
| miR-208a | ns | - | |||||
| miR-208b | ↑ | age, smoking, hs-TnT | |||||
| miR-499 | ns | male gender |
AMI acute myocardial infarction; AUC area under the curve; CHD coronary heart disease; CHF_II congestive heart failure, NYHA class II; CHF_III congestive heart failure, NYHA class III; CK-MB creatine kinase isoenzyme MB; eGFR estimated glomerular filtration rate; hs-TnT high-sensitive TnT; LAD left anterior descending artery; MI myocardial infarction; miR microRNA; nd not detected; non-op non-operated; ns not significant; NSTEMI non-ST elevation MI; ROC receiver operator characteristics; sham-op sham operated; STEMI ST elevation myocardial infarction; TnI troponin I; TnT troponin T; UAP unstable angina pectoris.